Thinking about broadly cross-reactive vaccines

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 6, 2009, Pages 665-668

  Doherty, P C ^a,b   Turner, S J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS A; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CROSS REACTIONS; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 67349086304     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.52     Document Type: Review

References (51)

1. Karlsson Hedestam, G.B., Fouchier, R.A., Phogat, S., Burton, D.R., Sodroski, J. & Wyatt, R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to infuenza virus. Nat. Rev. Microbiol. 6, 143-155 (2008).
2. Fauci, A.S. et al. HIV vaccine research: the way forward. Science 321, 530-532 (2008).
3. Bell, C.H. et al. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 375, 969-978 (2008).
4. Astronomo, R.D. et al. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodefciency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J. Virol. 82, 6359-6368 (2008).
5. Zhang, M.Y. et al. Cross-reactive human immunodefciency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J. Virol. 82, 6869-6879 (2008).
6. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
7. Forsell, M.N. et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog. 4, e1000171 (2008).
8. Keele, B.F. et al. Identifcation and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552-7557 (2008).
9. Thomas, P.G. et al. Hidden epitopes emerge in secondary infuenza virus-specifc CD8+ T cell responses. J. Immunol. 178, 3091-3098 (2007).
10. La Gruta, N.L. et al. A virus-specifc CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. USA 103, 994-999 (2006).
11. Stambas, J., Guillonneau, C., Kedzierska, K., Mintern, J.D., Doherty, P.C. & La Gruta, N.L. Killer T cells in infuenza. Pharmacol. Ther. 120, 186-196 (2008).
12. Smyth, M.J. et al. Unlocking the secrets of cytotoxic granule proteins. J. Leukoc. Biol. 70, 18-29 (2001).
13. Jenkins, M.R., Mintern, J., La Gruta, N.L., Kedzierska, K., Doherty, P.C. & Turner, S.J. Cell cycle-related acquisition of cytotoxic mediators defnes the progressive diferentiation to efector status for virus-specifc CD8+ T cells. J. Immunol. 181, 3818-3822 (2008).
14. Kedzierska, K., La Gruta, N.L., Turner, S.J. & Doherty, P.C. Establishment and recall of CD8+ T-cell memory in a model of localized transient infection. Immunol. Rev. 211, 133-145 (2006).
15. Kaech, S.M., Hemby, S., Kersh, E. & Ahmed, R. Molecular and functional profling of memory CD8 T cell diferentiation. Cell 111, 837-851 (2002).
16. Coles, R.M., Mueller, S.N., Heath, W.R., Carbone, F.R. & Brooks, A.G. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168, 834-838 (2002).
17. Flynn, K.J., Belz, G.T., Altman, J.D., Ahmed, R., Woodland, D.L. & Doherty, P.C. Virus-specifc CD8+ T cells in primary and secondary infuenza pneumonia. Immunity 8, 683-691 (1998).
18. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
19. Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
20. Turner, S.J., Doherty, P.C., McCluskey, J. & Rossjohn, J. Structural determinants of T-cell receptor bias in immunity. Nat. Rev. Immunol. 6, 883-894 (2006).
21. Berkhof, E.G. et al. Fitness costs limit escape from cytotoxic T lymphocytes by infuenza A viruses. Vaccine 24, 6594-6596 (2006).
22. Assarsson, E. et al. Immunomic analysis of the repertoire of T-cell specifcities for infuenza A virus in humans. J. Virol. 82, 12241-12251 (2008).
23. Frahm, N. et al. Control of human immunodefciency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7, 173-178 (2006).
24. Kedzierska, K. et al. Complete modifcation of TCR specifcity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy. Proc. Natl. Acad. Sci. USA 105, 19408-19413 (2008).
25. Price, G.E., Gaszewska-Mastarlarz, A. & Moskophidis, D. The role of alpha/beta and gamma interferons in development of immunity to infuenza A virus in mice. J. Virol. 74, 3996-4003 (2000).
26. Russell, C.J. & Webster, R.G. The genesis of a pandemic infuenza virus. Cell 123, 368-371 (2005).
27. Tumpey, T.M. et al. Characterization of the reconstructed 1918 Spanish infuenza pandemic virus. Science 310, 77-80 (2005).
28. Webby, R.J. & Sandbulte, M.R. Infuenza vaccines. Front. Biosci. 13, 4912-4924 (2008).
29. Lipatov, A.S., Hofmann, E., Salomon, R., Yen, H.L. & Webster, R.G. Cross-protectiveness and immunogenicity of infuenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J. Infect. Dis. 194, 1040-1043 (2006).
30. Hofmann, E., Krauss, S., Perez, D., Webby, R. & Webster, R.G. Eight-plasmid system for rapid generation of infuenza virus vaccines. Vaccine 20, 3165-3170 (2002).
31. Fedson, D.S. & Nichol, K.L. Infuenza vaccination: policy versus evidence: no gap between policy and evidence. BMJ 333, 1020 (2006).
32. Christensen, J.P., Doherty, P.C., Branum, K.C. & Riberdy, J.M. Profound protection against respiratory challenge with a lethal H7N7 infuenza A virus by increasing the magnitude of CD8(+) T-cell memory. J. Virol. 74, 11690-11696 (2000).
33. Eichelberger, M., Allan, W., Zijlstra, M., Jaenisch, R. & Doherty, P.C. Clearance of infuenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174, 875-880 (1991).
34. Epstein, S.L. Prior H1N1 infuenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193, 49-53 (2006).
35. Guillonneau, C. et al. Combined NKT cell activation and infuenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl. Acad. Sci. USA 106, 3330-3335 (2009).
36. McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity to infuenza. N. Engl. J. Med. 309, 13-17 (1983).
37. Webby, R.J. et al. Protection and compensation in the infuenza virus-specifc CD8+ T cell response. Proc. Natl. Acad. Sci. USA 100, 7235-7240 (2003).
38. He, X.S. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated infuenza vaccines. J. Virol. 80, 11756-11766 (2006).
39. Doherty, P.C. & Kelso, A. Toward a broadly protective infuenza vaccine. J. Clin. Invest. 118, 3273-3275 (2008).
40. Ledford, H. HIV vaccine may raise risk. Nature 450, 325 (2007).
41. Pantaleo, G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect. Dis. 8, 82-83 (2008).
42. McElrath, M.J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905 (2008).
43. Buchbinder, S.P. et al. Efcacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
44. Perreau, M., Pantaleo, G. & Kremer, E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205, 2717-2725 (2008).
45. Valentine, L.E. & Watkins, D.I. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol. 16, 605-611 (2008).
46. Doherty, P.C., Turner, S.J., Webby, R.G. & Thomas, P.G. Infuenza and the challenge for immunology. Nat. Immunol. 7, 449-455 (2006).
47. Cheung, C.Y. et al. Induction of proinfammatory cytokines in human macrophages by infuenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360, 1831-1837 (2002).
48. Lee, L.Y. et al. Memory T cells established by seasonal human infuenza A infection cross-react with avian infuenza A (H5N1) in healthy individuals. J. Clin. Invest. 118, 3478-3490 (2008).
49. Berkhof, E.G. et al. An amino acid substitution in the infuenza A virus hemagglutinin associated with escape from recognition by human virus-specifc CD4+ T-cells. Virus Res. 126, 282-287 (2007).
50. Galli, G. et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106, 3877-3882 (2009).
51. He, X.S. et al. Baseline levels of infuenza-specifc CD4 memory T-cells afect T-cell responses to infuenza vaccines. PLoSONE 3, e2574 (2008).